Related Experiment Videos
Effects of lipids on thrombotic mechanisms in atherosclerosis
Dimitris Tousoulis1, Graham Davies, John Ambrose
1Cardiology Unit, Hippokration Hospital, Athens University Medical School, S. Karagiorga 69, Greece.
Insights
Cholesterol-lowering therapy reduces cardiovascular events and improves atherosclerosis. Lipid levels are linked to blood clotting factors, with implications for heart disease treatment.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biochemistry
Background:
- Cholesterol-lowering therapy significantly reduces cardiovascular events and promotes regression of atherosclerotic lesions.
- Lipids are strongly associated with hemostatic factors like fibrinogen, plasminogen activator-1, and activated factor VII.
- Low-density lipoprotein (LDL) may promote thrombosis, while high-density lipoprotein (HDL) offers protection.
Purpose of the Study:
- To explore the intricate links between lipid metabolism and the body's blood clotting mechanisms.
- To understand how lipid-lowering treatments impact the thrombotic and atherosclerotic components of ischemic heart disease.
Main Methods:
- Review of existing literature on lipid profiles and coagulation factors.
- Analysis of the role of specific lipoproteins, such as LDL and lipoprotein (a), in thrombosis.
- Examination of the effects of statins on plaque stability and hemostasis.
Main Results:
- Lipid levels correlate with key coagulation factors, suggesting a role in thrombogenesis.
- Lipoprotein (a) may interfere with fibrinolysis, potentially promoting atherosclerosis and thrombosis.
- Tissue factor pathway initiates coagulation, leading to thrombin generation.
- Statins demonstrate plaque-stabilizing and antithrombotic effects.
Conclusions:
- There are significant connections between lipid profiles and hemostatic mechanisms.
- These connections influence the atherosclerotic, vasomotor, and thrombotic aspects of ischemic heart disease.
- Lipid-lowering therapies, particularly statins, offer benefits beyond lipid reduction by impacting hemostasis.
Abstract:
Cholesterol lowering therapy markedly reduces the frequency of subsequent cardiovascular events and is associated with a modest degree of angiographic regression of atherosclerotic lesions. There is a strong association between lipids and fibrinogen, plasminogen activator-1, and activated factor VII levels. Low density lipoprotein may be thrombogenic whereas high density lipoprotein protects against thrombosis. Lipoprotein (a) may affect atherosclerosis and thrombosis mainly by binding to fibrin and attenuating the fibrin-enhanced plasminogen activation. Tissue factor-complex initiates coagulation by activating factor X and factor IX leading in the presence of calcium to the generation of thrombin. Lipid lowering treatment with statins stabilizes atheromatous plaque and has antithrombotic effects. Therefore there are links between lipids and the haemostatic mechanisms which affect atherosclerotic, vasomotor and thrombotic components of ischemic heart disease.